TerminatedPhase 2

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

United States200 participantsStarted 2006-02

Plain-language summary

RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells can make an immune response against the body's normal cells. Methotrexate, cyclosporine, tacrolimus, or methylprednisolone may stop this from happening. PURPOSE: This clinical trial is studying how well a donor stem cell transplant or donor white blood cell infusions work in treating patients with hematologic cancer.

Who can participate

Age range

60 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following\*: * Acute lymphoblastic leukemia in any disease phase * Patients with any of the following high-risk features are encouraged to enroll: * Philadelphia chromosome positive disease * L3 morphology, especially in the presence of t(8;14), t(8;22), or t(2;8) * Patients not in remission at day 28 of first induction * High LDH (i.e., ≥ 300 IU/mL at presentation) * Pre-B-cell, mixed lineage, or Burkitt's markers * Relapsed in the marrow while receiving continuous chemotherapy * Within 6 months after stopping chemotherapy * Relapse in one organ or extramedullary relapses in more than one organ while still receiving chemotherapy * Hodgkin's or non-Hodgkin's lymphoma beyond first complete remission (CR) or in first CR with features of high-risk disease, including, but not limited to: * Lymphoma not in CR after 3 courses of primary therapy * Patients with bulky disease at presentation, especially bulky mediastinal disease * Patients with LDH ≥ 300 IU/mL at presentation * Patients with extranodal disease * Patients with first remission within less than 1 year * Stage IV disease at presentation, especially with marrow involvement * Patients with high-intermediate or high International Index Scores * Acute myeloid leukemia (AML) meeting the following criteria: * Beyond first remission or high-risk disease in first CR * Required multi…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of Participants With Disease Free Survival (DFS).

Timeframe: Duration of the study; Up to 2 years

Trial details

NCT IDNCT00281879

SponsorOHSU Knight Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-02

Results submitted2012-05-17

View on ClinicalTrials.gov More Chronic Myeloproliferative Disorders trials